ArticleFrontiers in oncology2026
APC-rearranged solid pseudopapillary neoplasm-pancreatic neuroendocrine tumor collision tumor: a molecularly resolved case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Solid-pseudopapillary neoplasm (SPN) is driven by CTNNB1 mutations, whereas pancreatic neuroendocrine tumors (PanNETs) harbor MEN1/DAXX/ATRX alterations. A true collision of the two entities has never been genetically proven. Case presentation: A 34-year-old man presented with a 4.2 cm pancreatic-tail mass and innumerable liver metastases. Distal pancreatectomy disclosed intimately admixed yet distinct SPN (90%) and G1 PanNET (10%). Targeted NGS revealed an in-frame APC rearrangement (Ex9-Int15); CTNNB1, MEN1, DAXX and ATRX were wild-type. Outcome: Following distal pancreatectomy and radiofrequency ablation of liver metastases, the patient remains asymptomatic with no evidence of disease progression at 9-month follow-up. Discussion: This is the first molecularly confirmed SPN-PanNET collision tumor driven by APC loss rather than CTNNB1 mutation. The case highlights the value of comprehensive genomic profiling when morphologic overlap obscures diagnosis and suggests that APC-driven SPNs may be more aggressive than previously thought.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.